

Beyond editing to writing large genomes

Raj Chari and George M. Church

Abstract | Recent exponential advances in genome sequencing and engineering technologies have enabled an unprecedented level of interrogation into the impact of DNA variation (genotype) on cellular function (phenotype). Furthermore, these advances have also prompted realistic discussion of writing and radically re-writing complex genomes. In this Perspective, we detail the motivation for large-scale engineering, discuss the progress made from such projects in bacteria and yeast and describe how various genome-engineering technologies will contribute to this effort. Finally, we describe the features of an ideal platform and provide a roadmap to facilitate the efficient writing of large genomes.

DNA reading (sequencing) and writing (synthesis) are intimately connected: meaningful use of either requires the other. For example, the most widely used sequencing platforms read DNA during the synthesis of a complementary strand^{1–3}. Targeted DNA reading, such as exome sequencing, depends on vast libraries of synthetic oligonucleotides for target capture, and the annotation and understanding of genome reads benefit greatly from genome-scale synthesis and testing. Furthermore, meaningful use of genome engineering generally requires whole-genome sequencing to design strategies for avoiding off-target writing and to verify the quality of the final genome product. Genome editing and writing have benefited from diverse nanomachines harvested by reading the biosphere. Since 1975, reading and writing platforms have exhibited increases in throughput of three-million-fold (for reading; see <https://www.genome.gov/sequencingcostsdata/>) and one-billion-fold (for writing of raw oligonucleotides)⁴, with a steep increase at an exponential rate since 2004. The technical progress of both reading and writing has depended not only on mere automation of human protocols but also on rethinking the whole process to permit miniaturization and multiplexing (in which millions of reactions

can be performed in the same space, at the same cost and with the same effort as a single reaction).

Although much of the attention has been on the progress in DNA reading, namely, advances in DNA sequencing technologies^{2,3}, the improvements in writing, which can largely be attributed to harnessing and stimulating natural cellular processes such as homologous recombination (HR) to enable genome modification, should not be overlooked. From the initial work of describing HR at a very low level in higher-order eukaryotic cells to current work, where we can achieve reasonably high efficiencies of HR in stem cells^{4–7} (FIG. 1), our ability to direct targeted changes in genomes has opened a large number of avenues that previously may not have seemed possible.

One of the main areas that can be realistically pursued is the ability to perform large-scale editing of genomes, even multiplexing libraries of billions of changes⁸. From an industrial perspective to a health care perspective and to researchers aiming for fundamental understanding of how biological systems work, the motivations to pursue ambitious genome-engineering projects originate from a diverse group of stakeholders, and the results of these projects could have considerable positive impact on multiple aspects of society. Combining

the technological advancements in genome engineering with those in both DNA synthesis and DNA sequencing, the key components that are necessary to approach large-scale genome engineering have fallen into place.

In this Opinion article, we describe the motivation for and current state of large-scale genome engineering and compare strategies for how it can be achieved. We provide an overview of key genome-engineering technologies and how they can be utilized for large-scale editing. Finally, we detail the key features that will be necessary for a robust genome-writing platform and provide a roadmap to engineer a large genome. As seen for whole-genome reading, the cost and quality of methods for genome writing are improving by factors of millions, and rigorous, comprehensive tests for the accuracy of genome writing will shift from being a luxury to becoming essential and routine.

Why should we engineer genomes?

When we refer to genome engineering and genome editing, our use of ‘genome’ specifically means large-scale engineering or alteration of several loci across the genome. We feel that such terminology is unhelpfully misapplied when referring to single-locus applications, such as using genome engineering to refer to editing that is done directly in the genome rather than in a plasmid or transgenic setting or using the term genome editing when the changes are neither precise editing nor genome scale. The question for this section is why should we design and generate whole (or nearly whole) genomes? An initiative known as *Genome Project-write* has recently advocated large-scale genome engineering⁹. The motivation and goals are well aligned for both small-scale and large-scale genome engineering. With respect to non-human organisms, bacteria are common chassis for various bioproduction applications, from uses in bioremediation to pharmaceuticals to bioenergy^{10–12} (FIG. 2). From a purely functional perspective, re-engineering the genomes of particular strains could render the bacteria less susceptible to viruses and/or more efficient at producing a biomolecule of interest^{13,14}. Similarly, yeast strains, plants




Figure 1 | Timeline of gene targeting. The timeline depicts progress in gene targeting rates through recombination (red) and the number of edited sites in a single genome (blue). Recombination rates with dashed lines denote ranges observed in the published literature^{4,27,28,50,58,63,64,125–147}. In the mid to late 1980s, it was observed that in the presence of exogenous DNA, homologous recombination (HR) could occur at a very low frequency (0.01%). Subsequently, it was shown that by inducing a double-strand break (DSB), the rates of HR could be dramatically increased. Thus, different modalities have been discovered and employed to create DSBs at higher frequencies, from meganucleases (such as I-SceI) to zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) to the current CRISPR-associated nucleases. In addition, approaches that do not use DSB-stimulated HR, such as Cre recombinase or phiC31 integrase, have also shown tremendous promise for DNA replacement but are restricted by the limited range of sequences that can be targeted. As a corollary, in combination with the progress in DNA synthesis technologies, our improved ability to edit DNA has permitted increases in the total number of modifications being made in a single genome. In the past, 1 to 2 edits were typically made in a single genome. Ambitious projects such as RC57 and Sc2.0 have aimed to make up to four or even five orders of magnitude more edits in a single genome.

and livestock could be thought of in the same manner, and re-engineering their genomes could ensure the highest and most efficient productivity. For some of these particular entities, genome engineering could address global problems such as food shortages and environmental deterioration, for example, by altering sets of genes in metabolic pathways to permit either increased or reduced production of specific biomolecules. Thus, the ability to perform genome engineering at a larger scale would enhance our chances of achieving these goals.

Genome-wide association studies (GWAS) along with large-scale high-throughput sequencing of exomes and genomes have uncovered hundreds, if not thousands, of small and large DNA sequence variations associated with a given phenotype, including medically important human traits¹⁵. For example, in numerous genetic disorders, studies are advancing from correlation to cause and effect (for instance, via genome engineering in animals or organoids) to prove that particular

mutations are the likely causes and drivers of specific diseases^{16–22}. Subsequently, from a therapeutic perspective, repair of such defects would probably necessitate small-scale genome editing only, whereby a limited number of genomic targets would need to be altered in order to restore normal function. Whether the alteration becomes a lasting cure for the disease will largely depend on the proportion of target cells in which editing is achieved and the persistence of the edited cells in their biological niche.

The proportions and persistence of edited and unedited cells are particularly important in diseases such as cancer, where residual unedited, defective cells may have acquired a selective growth advantage over edited cells that could confer them with the ability, over time, to eliminate edited cells from the population.

It is also clear that many normal and disease phenotypes are governed by concurrent genetic variants across multiple alleles throughout the genome. Large-scale genome editing would enable, in the immediate term, the understanding of complex genotype–phenotype associations. From a more ambitious perspective, engineering human cells to be less susceptible to disease and generating tissues to eventually produce organs of high value are additional applications that would require large-scale genome editing. Thus, it is likely that the most immediate impact from editing human cells will emanate from small-scale engineering, whereas large-scale approaches will be crucial for obtaining a better understanding of phenotypes with complex genetics.

Tactically, if the number of desired changes is large and the changes span different areas of the genome, there is a compelling reason to approach this problem in a completely synthetic manner. From a practical perspective, this approach is currently limited to genomes that are megabases in size (at most), such as those in unicellular organisms. Here, rather than modifying an existing genomic template, designing and building the genome of interest completely from chemically synthesized DNA would not only provide the most efficient way to incorporate many changes into a desired DNA target but also enable complete control of the final sequence. The most compelling cases so far have included extensive changes in the genetic code (for biocontainment, efficient

Glossary

Homologous recombination

(HR). Exchange of sequence between two highly similar DNA molecules.

Homology-directed repair

(HDR). The process by which double-strand breaks (DSBs) in DNA are repaired when in the presence of an additional DNA moiety that has homology to the DNA sequence surrounding the DSB.

Protospacer adjacent motif

(PAM). A short, characteristic sequence (typically between 3 and 8 nucleotides in length) that the

CRISPR-associated nuclease (such as Cas9 or Cpf1) recognizes before making its DNA break. Depending on the CRISPR system used, this sequence must either flank the 3' end or 5' end of the sequence of interest.

Reading

The use of massively parallel sequencing technologies to decipher nucleotide composition.

Writing

The use of either genome-editing tools and/or DNA synthesis to make desired changes in DNA sequence.

Applications from engineered organisms




Figure 2 | Potential applications of large-scale genome engineering of different organisms. For applications such as bioenergy, chemicals, proteins and vaccines, the goal is to increase production by engineering metabolic pathways in particular organisms. Similarly, engineering of the metabolic pathways in these organisms could be used for environmental remediation, from maintaining clean water supplies to removing pollutants and CO₂ from the air. While for applications such as food supply, in addition to making plants and livestock larger, large-scale engineering of regulatory

variants aims to make these sources grow more robustly (that is, tolerant to different environmental conditions) and to be less susceptible to disease to minimize loss. Finally, for mammalian genome engineering, some of the main key applications would be for deciphering complex genotype-phenotype relationships, modelling disease and producing cells of interest. Subsequently, these engineered cells could be built into tissues and organs *ex vivo* using approaches such as 3D printing or, if the engineering was performed in pigs, organs could be harvested for xenotransplantation.

use of non-standard amino acids and multi-virus resistance) and ‘refactoring’ to reveal the absence or presence of unknown regulatory motifs^{23–25}.

Genome-editing systems — not just Cas9

The excitement and enthusiasm surrounding the ability to edit large regions and genomes can be mainly attributed to the recent developments in genome-engineering technologies. Much of the spotlight has been on the CRISPR–Cas9 system from *Streptococcus pyogenes* that has been repurposed and adapted for genome engineering in human cells^{26–28}. However, we have access to a large number of genome-editing nanomachines, most of which have different mechanisms of action. Broadly, these tools can be classified by how the system recognizes its target site, that is, using DNA, protein or RNA (FIG. 3; TABLE 1), and whether they make double-strand breaks (DSBs).

DNA-based target recognition. For DNA-based target recognition systems (FIG. 3a), the two major approaches, multiplex automated genome engineering (MAGE) using λ -red recombination⁸ and conjugative assembly genome engineering (CAGE)¹³, have been widely used in prokaryotes and have demonstrated a high degree of multiplexability. Briefly, the λ -red system, similar to recET²⁹, originates from phage and, when imported into bacterial cells, can stimulate high levels of recombination in the presence of homologous DNA³⁰. Although the machinery used in these approaches has not been fully optimized for eukaryotic cells, some conjugal transfer has been demonstrated³¹, and the use of an optimized version of Red β in human cells has yielded limited success³². Moreover, these technologies can be used to edit and propagate large pieces of DNA in bacteria for eventual use as donor DNA molecules for HR in human cells.

Transfection of single-stranded oligonucleotides (SSOs) alone can also be used to create small, site-specific insertions, deletions and substitutions. Typically, these oligonucleotides range between 20 and 200 bases in length, may contain modified bases to increase stability and have a high degree of homology to the target site. Mechanistically, during DNA replication, in a very small percentage of instances, SSOs will be used as a template, and the change encoded by the SSO will be incorporated in the host genome. SSOs alone have demonstrated efficiencies ranging from 10^{–5} to 2% in

mammalian cells^{33–35} (TABLE 1). However, the most prevalent utility of SSOs is in conjunction with a designer nuclease to generate much higher rates of modification^{5,36}.

The Argonaute protein (Ago) from the bacterium *Thermus thermophilus* (TtAgo) has been shown to provide DNA-based DNA interference, where a single-stranded DNA guide could direct Ago-based cleavage of a plasmid DNA target, albeit only at temperatures $\geq 65^\circ\text{C}$ (REF. 37). Editing activity in human cells using TtAgo has not been published. Although a different Ago from *Natronobacterium gregoryi*, NgAgo, was initially reported to edit DNA in eukaryotic cells at physiological temperatures³⁸, these results were questioned^{39–41} and the original paper was subsequently retracted. If an Ago-based system can be shown to have reliable cleavage efficacy at DNA target sites in eukaryotic cells, a key potential advantage is that, unlike CRISPR–Cas9, there is no requirement of a protospacer adjacent motif (PAM) which would, in theory, make any DNA targetable for editing.

Protein-based target recognition. The majority of systems use protein-based target recognition, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases and tyrosine/serine site-specific recombinases (Tyr/Ser SSRs) (FIG. 3b). ZFNs and TALENs recognize DNA target sites, ranging from 25 to 40 bp in size, in a sequence-specific manner through their DNA-binding domains and generate staggered DSBs through the action of FokI nuclease domains on opposite DNA strands. These systems

have previously been discussed in great detail and, thus, will not be elaborated further here^{42,43}. Meganucleases, also known as homing endonucleases, recognize a specific DNA sequence between 14 and 40 bp upon which they cut and induce a DSB⁴⁴. The efficiencies of meganucleases are reasonably high, and they only require a single custom biopolymer for each target site. However, the natural repertoire of targeting sites is quite limited. To address this key limitation, work has been done to systematically increase the diversity of targeting sites using mutagenesis approaches and by deriving fusions to programmable DNA-binding domains^{45–48}.

Tyr/Ser SSRs, which typically recognize target sequences between 30 and 40 bp in length, were one of the earliest genome-engineering tools to enable homology-directed repair (HDR) in mammalian genomes^{49,50}. Briefly, the target site comprises three parts, a short DNA sequence flanked by two inverted repeats, and recombination can occur between a pair of target sites, where the DNA sequence between the target sites can be deleted, inverted or replaced. Notably, whereas Tyr SSRs utilize a mechanism of strand exchange without creating DSBs, Ser SSRs do create DSBs, but unlike simpler designer double-strand nucleases, SSRs require concerted cleavage and re-ligation with the donor DNA present⁵¹. Although this mechanism of genome engineering is highly efficient in both prokaryotes and eukaryotes, the requirement of two naturally occurring copies of a very specific target site in relatively close proximity is limiting, and there are very few Tyr/Ser SSRs that

Figure 3 | DNA-editing nanomachines. a | DNA-based recognition. Multiplex automated genome engineering (MAGE) utilizes machinery from the phage λ , namely, the single-stranded binding protein beta and an exonuclease (Exo). Designer oligonucleotides, along with these two proteins, can enable the incorporation of desired changes at multiple genomic locations⁸. Conjugative assembly genome engineering (CAGE) enables the hierarchical assembly of parallel edited genomes. For every pair of edited genomes (strains), one strain is designated a donor strain and the other a recipient strain such that the direction of DNA transfer is engineered to be in a single direction¹³. This cycle can be repeated until the result is a single strain with all desired changes. The Argonaute (Ago) system utilizes a 24-nucleotide guide DNA sequence along with the Ago protein to direct a double-strand break (DSB) in a site-specific manner. **b** | Protein-based recognition. Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and meganucleases utilize staggered-end forming DSBs to facilitate DNA editing. A new custom protein is required for each targeted site. Tyrosine (Tyr) and serine (Ser) site-specific recombinases (SSRs) mediate editing with (Ser) or without (Tyr) using DSBs. A pair of short inverted repeats (IRs), flanking both the target site and donor DNA molecule, are required for DNA to be exchanged. Currently, the repertoire of different recombinase recognition sites is quite limited. **c** | RNA-based recognition. Group II introns encode both a self-catalysing RNA moiety and a reverse transcriptase (RT), which enable site-specific disruption within a sequence of interest. The CRISPR–Cas9 system has demonstrated the most promise among current genome-engineering technologies. A single-guide RNA (sgRNA) specifies the location in which a blunt-end-forming DSB is made by the Cas9 protein and, due to this simplicity, enables simultaneous targeting of multiple sites by including multiple sgRNAs. Protein crystal structures were generated using Chimera¹⁴⁸, and Protein Data Bank (PDB) accession numbers are provided underneath each structure^{149–157}.









a DNA-based recognition**Argonaute****b Protein-based recognition****Zinc-finger nuclease (ZFN)****Transcription activator-like effector nuclease (TALEN)****Meganuclease****Tyr/Ser site-specific recombinase (SSR)****c RNA-based recognition****Group II intron****CRISPR-Cas9**

Table 1 | Properties of DNA-editing nanomachines

Name	Target scanning	Use in human cells	Target diversity	Double-strand break	Maximum number of simultaneously altered sites*	Maximum observed HDR (%) [‡]	Maximum observed NHEJ (%) [‡]	Refs
Unstimulated endogenous HR	DNA	Yes	High	No	2	10 ⁻⁶	NA	158
MAGE (λ-Red)	DNA	Yes	High	No	2 [†]	NA	NA	32,159
CAGE	DNA	No	High	No	NA	NA	NA	13
SSOs only	DNA	Yes	High	No	2	10 ⁻⁴	NA	33,35
ZFNs	Protein	Yes	Moderate	Yes [§]	6	43	65	160–162
TALENs	Protein	Yes	High	Yes [§]	2	10	50	6,163
Meganucleases	Protein	Yes	Low	Yes	2	1	5	164,165
Tyr/Ser SSRs	Protein	Yes	Low	No	6	10 ⁻⁵	NA	166
Group II introns	RNA	Yes	High	Yes	NA	NA	NA	58,59
CRISPR–Cas9	RNA	Yes	High	Yes [§]	62	33	79	7,70,167

*In mammalian cells (per individual genome). Homozygous changes counted as two altered sites. [‡]Observed in mammalian stem cells without antibiotic selection. [§]Can be programmed as nickases (single-strand nucleases). ^{||}Although Ser SSRs utilize double-strand breaks mechanistically, these breaks are probably not exposed to the NHEJ machinery in the manner of the various designer nucleases. [†]In bacteria, 12 sites have been simultaneously edited. CAGE, conjugative assembly genome engineering; HDR, homology-directed repair; HR, homologous recombination; MAGE, multiplex automated genome engineering; NA, data not available or not applicable; NHEJ, non-homologous end joining; SSO, single-stranded oligonucleotides; SSRs, site-specific recombinases; TALENs, transcription activator-like effector nucleases; ZFNs, zinc-finger nucleases.

recognize different target sites. However, the potential for recombinases in the scheme of large-scale genome engineering is vast; thus, work to increase the diversity of DNA sequences that SSRs can target by engineering new specificities, which has already started and is continuing^{52–57}, will be highly valuable.

RNA-based target recognition. The class of RNA-based target recognition includes group II introns and CRISPR–Cas9 (FIG. 3c). For group II introns, in a process known as retrohoming, DNA is first transcribed into a catalytically active RNA and an mRNA encoding a reverse transcriptase. These two components form a complex and invade DNA with sequence similarity to a part of the intronic RNA. Subsequently, reverse transcription of the RNA molecule into cDNA permits insertion in a targeted manner to disrupt gene function or, when homologous DNA is introduced, to promote HDR^{58,59}. At the current juncture, this technology is not likely to be a main contributor to large-scale genome engineering owing to its low activity in mammalian cells.

Finally, the CRISPR–Cas9 system has been shown to be one of the most robust gene-editing platforms currently available^{26–28}. Review articles have covered the development of the CRISPR–Cas9 system in terms of its mechanism of action, ability to be tethered to different effector domains, and improvements in terms of higher specificity and multiplex editing

potential^{42,60–62}. Furthermore, specific variants of Cas9 have been made to enable gene editing without creating DSBs. A single mutation to the Cas9 protein can generate a version that only creates a single-strand DNA cut (nick)^{63,64}. Fusion of a nuclease-dead Cas9 (dCas9) to a cytidine deaminase enables site-specific conversion of cytidine to uracil^{65–67}. With respect to large-scale genome editing, the key relevant aspect of CRISPR is the ease of designing and multiplexing single-guide RNAs (sgRNAs) for targeting diverse genomic loci, which could enable excision and/or replacement of DNA segments of various sizes. This aspect has been demonstrated in the epigenetic context of studying enhancer function^{22,68,69}, multi-kilobase gene replacement⁶ and multiplexed disruption of 62 different porcine endogenous retrovirus (PERV) sites in the pig genome⁷⁰.

Genome editing versus *de novo* synthesis

Various strategies have been outlined to perform large-scale genome engineering, from completely synthesizing genomes *de novo*, to massively editing an existing genome scaffold, to a combination of both⁷¹. In a fully synthetic approach, genomes of interest are designed computationally, and then a rational, hierarchical strategy is devised to assemble long oligonucleotides into larger pieces (FIG. 4a). Alternatively, an existing genome scaffold can be substantially edited, whereby the scaffold is delineated into a manageable number of segments of roughly equal size, and then

each segment is edited independently using an approach such as MAGE or CRISPR (FIG. 4b). Subsequently, these segments can be re-assembled into the final desired sequence. In this section, we describe successful applications of large-scale engineering in bacteria and yeast and how these approaches could be translated for higher-order eukaryotes.

Previously, our laboratory engineered an *Escherichia coli* strain in which all known instances of the UAG stop codon were replaced with UAA, with the motivation of freeing the UAG codon to encode for novel amino acids^{13,14}. In this work, the *E. coli* genome was separated into 32 different segments, such that each segment contained approximately 10 UAG codons, then these segments were edited in parallel using MAGE. Briefly, MAGE utilizes the phage λ-red recombination machinery along with short oligonucleotides carrying desired mutations to enable cumulative recombination in a cyclical process that can be repeated multiple times. Once each segment obtained all the necessary UAG changes, the segments were hierarchically assembled into a single strain using CAGE. Notably, this final strain exhibited decreased phage infectivity, and the UAG codon was successfully re-assigned to different non-standard amino acids^{14,24,25}, demonstrating that this approach can be used to create potentially industrially robust strains.

By contrast, genomes have also been constructed completely *de novo* from synthesized DNA. Work from the J. Craig



a Complete *de novo* synthesis**b Editing an existing DNA scaffold**

Figure 4 | Two main approaches to large-scale genome engineering in bacteria and yeast. **a** | For complete *de novo* synthesis, one must first computationally design oligonucleotide sequences that comprise the desired product while ensuring the highest compatibility with the experimental strategy used for assembly. For example, the thermodynamic properties of the sequence, such as GC% and secondary structure formation, are important parameters to consider. Subsequently, oligonucleotides (~150–200 bases in length) can be assembled into 1–2 kbp fragments using *in vitro*

PCR-based approaches. Finally, these fragments can be assembled into segments in the order of megabase pairs (Mbp) by use of either bacteria or yeast as a chassis. **b** | Extensive editing of an existing genome scaffold. Depending on the size of the DNA segment being edited, a segment is computationally divided into pieces with an approximately similar level of editing. Each piece can then be edited independently in bacteria or yeast and, upon completion, can be re-assembled into a single final segment and then placed into the final recipient cell.

Venter Institute (JCVI) has resulted in the synthesis of numerous small genomes^{72–75}. Here, the eventual goal was to generate a minimal genome (JCVI-syn3.0) using a completely synthetic genome (JCVI-syn1.0) as the starting point. Briefly, for JCVI-syn1.0, the approach taken was to hierarchically assemble 1-kb DNA fragments into larger and larger segments by use of HR in yeast and to subsequently transfer the constructed genome (~1 Mbp in size) into a new recipient strain⁷⁶. Similarly, our group recently used synthesized DNA fragments for an entire *E. coli* genome (~4 Mbp in size) along with yeast HR for assembly to re-design the *E. coli* genome to use 57 out of 64 codons, enabling re-assignment of the seven unused codons to additional, non-standard amino acids⁷⁷.

In yeast, the major project that is well underway is the Synthetic Yeast Genome Project (Sc2.0)^{78,79}. Sc2.0 utilizes a full synthetic approach whereby chromosomes (or chromosome arms) are made entirely from chemically synthesized DNA. Two chromosome arms (synIXR and semi-synVII) were synthesized *de novo* as a bacterial artificial chromosome (BAC)

and transformed into yeast; subsequently, the native wild-type versions of these arms were inactivated. By contrast, for synthesis of chromosome III, a hierarchical approach was taken. Starting from thousands of short nucleotides (70 bases), ~400 building blocks (750bp) were assembled using PCR-based protocols to produce 83 overlapping segments (2–4 kbp) in yeast by HR. For the replacement of the native chromosome, synthetic segments were iteratively replaced over multiple cycles until the entire chromosome was replaced. Most recently, in addition to chromosome III, synthetic versions of chromosomes II, V, VI, X and XII have been made, marking the completion of more than one-third of the chromosomes in the Sc2.0 project^{80–84}.

Technical challenges

It is clear that both large-scale editing of existing scaffolds and *de novo* synthesis of DNA have yielded successful end products, each with its own advantages and disadvantages. Furthermore, when scaling these approaches to larger genomes (such as human), additional considerations would also need to be addressed. Here, we discuss a number of key technical challenges, many

of which are shared by both approaches, and potential solutions.

Although computationally designing and subsequently producing chemically synthesized DNA offers much greater control than starting from existing genomes, the cost to synthesize an entire human genome is probably more expensive than editing an existing scaffold. It should be noted that this cost comprises the raw materials (synthetic DNA) and the process and labour of assembling the raw material into the final product. Thus, a further reduction in cost will be necessary. However, this difference in cost is much smaller than it once was, as we have observed a million-fold reduction in cost in a decade for genome sequencing⁸⁵ and solid-phase DNA synthesis⁸⁶, to the point where the cost for sequencing is about US\$1,000, whereas synthesis runs about US\$6,000 (REF. 9) per human genome. Furthermore, genomic regions with low sequence complexity (that is, those that are highly repetitive) can also pose difficulties with current DNA synthesis platforms. Relatedly, the genome sequences of many higher-order eukaryotes are

incomplete, largely due to difficulties with reading low-complexity genomic regions. For example, further development and application of newer sequencing technologies that can generate long reads, such as those obtained from Pacific Biosciences (PacBio) single-molecule real-time (SMRT) sequencing⁸⁷ and Oxford Nanopore Technologies (ONT) nanopore sequencing^{88–91}, or high-resolution visualization approaches could be used to complete our maps of these genomes⁹².

Massively editing an existing scaffold also has limitations and consequences. First, the multiple rounds of editing required to achieve the desired genome sequence can be quite laborious and time consuming to perform. If the efficiency for multiple targeting is not sufficiently high, cell populations would need to be screened for the correct sequence over each iteration. Second, depending on the genome-editing technology used, the sequence of the genome itself can present challenges in targeting. For example, regions with a high per cent of cytosines could present challenges for site-specific deaminases and/or regions that are A/T-rich would present problems for CRISPR–Cas9. The discovery of the CRISPR system Cpf1 nuclease (as an alternative to Cas9) could address the latter problem, as the PAM is composed of a thymidine homopolymer⁹³.

A notable consequence of genome editing is the targeting of unintended sites. Targeting particular single-nucleotide variants (SNVs) or point mutations is difficult because all the genome-editing platforms can tolerate some level of mispairing. For unintended mutagenesis, the use of a non-DSB-inducing technology could alleviate this problem, but in general, the efficiencies of these approaches are lower than the efficiencies of DSB-inducing technologies. Thus, if a DSB-inducing approach were used, any off-target sites that are unintentionally altered could be identified in a high-throughput manner^{61,94–97}, and even if there were DSBs, these could still be tolerated if the DSBs were not introduced in important regions in the genome, such as oncogenes or tumour suppressor genes. Similar to the above suggestion, an iterative approach could be used whereby after each iteration, the target DNA is sequenced to verify the absence of off-target mutations. However, as the number of iterations required increases, the costs associated with sequencing would also increase.

For both *de novo* genome synthesis and substantial editing of existing genomes,

designing and introducing many changes at once relative to the normal genome sequence may result in a non-viable phenotype as a consequence of the editing process itself (in the case of radically modifying an existing scaffold) or as a result of the DNA sequence being incompatible with normal function. Although we have gained a better understanding of how to design prokaryotic and lower-order eukaryotic genomes⁸⁰, this level of understanding does not exist for more complex mammalian genomes. Thus, it may be imperative that the upper limit of the number of modifications that can be made in a single iteration be identified for each cell type, and if the number of changes exceeds this limit, the modifications would be incorporated in multiple iterations.

As each approach provides distinct advantages and challenges, it may very well be a hybrid of these two approaches that will ultimately be most successful. One can envision a scenario in which an initial library of DNA building blocks that spans an entire genome will be synthesized (or generated through PCR of genomic DNA), and subsequent sequence variations to particular sets of building blocks will be generated using genome-engineering technologies. For example, starting with a BAC library comprising overlapping 100–300 kbp segments of the human genome⁹⁸, one can select an individual BAC encompassing a desired genomic location, edit this DNA segment in *E. coli* using MAGE and subsequently use HR to incorporate this new DNA segment in the destination cell population.

Desired genome-writing properties

We have detailed two different approaches to performing large-scale genome engineering. Although building large genomes *de novo* has many advantages, as we stated earlier, we believe that a combination of *de novo* DNA synthesis and genome-editing technologies will probably be utilized moving forward. Thus, it will be important to understand what properties we desire in a truly robust, high-throughput genome-writing platform (TABLE 2).

Of the different genome-engineering technologies described, although it has not been shown to work in human cells, the λ -red (and the similar recET) recombination systems have the ideal characteristic that only one custom biopolymer (the donor DNA molecule carrying desired changes) is necessary to make site-specific changes, whereas the other technologies require at least two. For

example, for CRISPR–Cas9 or TALENs and ZFNs, each target site would require a new sgRNA or new designer nuclease, respectively, in addition to the donor DNA molecule specifying the new sequence.

Next, the majority of editing experiments have been performed in cells that are continually undergoing mitosis, so another ideal feature would be a system that can also operate in postmitotic cells in a highly efficient manner. Although the level of editing desired in postmitotic cells may not be as large in scale as the level desired in other cells, this feature would at least increase the repertoire of cell types that could be edited. To date, Cre recombinase and CRISPR–Cas9 have been shown to be effective in cardiomyocytes and neurons, respectively^{99–101}, with application in other cell types yet to be demonstrated.

In addition to increasing the diversity of cell types, it is also important to be able to have broad target sequence specificity. As mentioned earlier, if Ago systems could be optimized in the future for efficient DNA target cleavage in eukaryotic cells, one of their more compelling features is the lack of a requirement for a PAM sequence. Although this system would provide a theoretically unlimited range of targetable sequences, it may also increase the likelihood of unintended mutagenesis via off-target activity. In the same vein, when improving CRISPR–Cas9 specificity, depending on the approach taken, a reduction in off-target activity may be accompanied by a reduction in on-target activity as well⁶¹. Thus, it is going to be a fine balance of having a system that has a broad targeting range, high editing efficiency and high specificity.

The ability to achieve 100% gene disruption at a single locus has become feasible for some loci with many of the technologies discussed. However, the ideal feature with respect to efficiency is obtaining a high frequency of multiplexed editing where we have the ability to make hundreds of changes per cell simultaneously. Highly efficient multiplexed editing would need to be done in conjunction with an approach that minimizes toxicity to the cell. If the method of choice utilizes DSBs, creating hundreds of DSBs could be problematic in that it could either induce cellular apoptosis or chromosomal rearrangement. As highlighted earlier, the disruption of 62 PERV genes in a single genome with minimal impact on genome architecture was probably a unique case, as there were no apparent rules for multiplex targeting that could be

Table 2 | Ideal features for genome writing or editing platforms

Feature	Description
Simple	Only one custom biopolymer for each HDR or HR event
Multiplex	100% targeting at multiple sites, not merely 'high efficiency' at a single site
Robust	High efficiency in postmitotic cells (for example, neurons), broad sequence compatibility
Large regions	High efficiency of 10 kbp to 10 Mbp scale replacements, alternative strategies possible
Low toxicity	Low apoptosis, high specificity, genome integrity intact
Germline editing	Specific safeguards might include restriction to gametes and/or clonal analysis to reduce mosaicism
Reading and testing	Rapid feedback on many synthetic genomes via reporters, organoids and sequencing

HDR, homology-directed repair; HR, homologous recombination.

discerned moving forward, and only a single sgRNA was required to target all 62 sites⁷⁰. Thus, a more sophisticated strategy, such as manipulating DNA repair machinery or utilizing non-DSB-inducing entities, would be necessary if this many genes were simultaneously targeted in other applications.

Nonetheless, this level of disruption will be crucial for large-scale editing. Although efforts have been made to identify approaches to improve HR and HDR, the efficiencies are still typically one order of magnitude lower than that of an alternative mechanism of DSB repair, non-homologous end joining (NHEJ), in which the DNA ends are re-ligated, typically without incorporating a donor DNA sequence^{102–107}. Intriguingly, attempts to utilize the NHEJ repair pathway to incorporate specific DNA sequences have also been made with some degree of success^{108,109}. Thus, work will need to continue to identify innovative ways to achieve high editing frequency simultaneously across multiple loci.

Relatedly, another important feature will be to increase the efficiency of larger changes. There is an inverse relationship observed between the efficiency of an alteration and the size of the alteration, where smaller changes are much easier to incorporate than larger ones^{6,110}. Two potential strategies could be pursued to address the efficiency. The first strategy would be to utilize recombinases, and the second would be to tether homologous DNA directly to genome-editing reagents. Recombinase-mediated cassette exchange (RMCE) has been routinely used in mammalian cells, with its most prevalent use in creating conditional mouse strains^{111–114}. This approach requires two separate gene-editing events — one event to place recombination sites flanking the area

to exchange and then the exchange event itself — and thus could be quite laborious. Intriguingly, RMCE has been combined with CRISPR–Cas9 to make this approach more efficient¹¹⁵. As stated previously, the main challenge with recombinases is the limited diversity of targetable sites. In terms of tethering or pairing, placing the donor template in close proximity to the site of cleavage should increase the frequency at which replacements occur. For example, when using CRISPR–Cas9, the desired proximity could be ensured by covalently attaching the donor DNA to the sgRNA.

Last, but not least, is germline editing. The ability to edit the germline poses the usual ethical issues of risks, benefits, safety and efficacy (adequately handled by organizations such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the China Food and Drug Administration (CFDA))^{116–119}. One of the most difficult challenges, from a logistical perspective, will be understanding the long-term, potentially trans-generational, societal impact of germline editing applications, which may otherwise be deemed 'safe' in a conventional medical sense. Ironically, because reproductive technologies, such as spermatogonial stem cell engineering, can use clonal sibling cells, which can be checked for genomic goals, including zero undesired on-target mutations (caused by NHEJ rather than HDR), off-target errors and epigenetic issues, high-fidelity editing may be more critical for somatic gene therapy. Additionally, editing sperm or egg precursor cells could result in considerable reduction in embryo loss and spontaneous or induced abortion relative to *in vitro* fertilization (IVF) and hence might be attractive to recessive carrier parents with concerns about

risks to embryos. At this juncture, it seems difficult to draw sharp red lines for what may be permitted versus forbidden; for example, designating areas of the genome, such as the mitochondrial genome, where editing would be permitted. It should also be noted that mitochondrial replacement therapy has already been utilized in cases of IVF¹²⁰. A key component will be engaging various communities to imagine unexpected scenarios, including respect for diverse cultures and faiths.

A roadmap to writing large genomes

After these desired features of a large-scale genome-writing platform are achieved, the final step is implementation. Here, we consider a roadmap for how the implementation could be accomplished (FIG. 5). Starting with libraries of DNA oligonucleotides, small DNA fragments in the 3-kbp range can be constructed *in vitro* using a combination of DNA annealing, ligation and amplification. By taking advantage of the high efficiency of HR in yeast, these smaller fragments could then be assembled into larger pieces of approximately 50 kbp in size (or possibly into the megabase scale). Next, these 50-kbp segments can be built into larger fragments (~4 Mbp) using an SSR system in *E. coli*. Multiple bacterial or yeast strains carrying different 4-Mbp fragments could be delivered via conjugation (or spheroplast fusion) to plant or animal cells to build chromosome-sized elements^{31,121}. Finally, these large (40–250 Mbp) segments could be hierarchically assembled (usually with selectable markers) into single cells by microcell-mediated chromosomal transfer (MMCT)¹²². As the efficiency of HR increases, we can miniaturize and multiplex the HR reactions and reduce the need for selection. High-throughput and multiplex testing of large numbers of combinatorially created genomes greatly increases the chances of rapid success.

It should also be noted that at various points of this process, DNA segments of different sizes could be modified using smaller-scale genome-editing technologies, contingent on the ability to retrieve and replace individual segments efficiently (such as using a multiplex barcoded library). Additional editing is advantageous for various reasons. First, if a particular segment was deemed incompatible for viability, the segment could be edited until it no longer created problems. Second, if additional sequence diversity was desired, it may be more efficient to edit the DNA segment than to re-synthesize it entirely.




Figure 5 | A roadmap to building large genomes using a combination of *de novo* synthesis and genome editing. Here, a hierarchical strategy is employed starting from short oligonucleotides (150 to 200 bases in length), which can be assembled into short DNA fragments ~3 kbp in size. The short DNA fragments are then be assembled into larger segments between 50 kbp and 1 Mbp in size. Segments ~4 Mbp in size can be built in bacteria or yeast and subsequently transferred into human cells by conjugation. These segments can then be increased to ~100 Mbp in size and transferred into recipient cells by microcell-mediated chromosomal transfer (MMCT). In each stage where a segment is built, genome-editing tools, such as multiplex automated genome engineering (MAGE), CRISPR, homologous recombination (HR) and site-specific recombinases (SSRs), can be utilized to make further edits from what was specified in the initial set of oligonucleotides.

For example, if the editing was to be performed in yeast, native HR could be used, which is already highly efficient, or a CRISPR-based approach could be used for replacement^{123,124}. Similarly, if the segments were in *E. coli*, MAGE and/or CAGE could be employed.

Taken together, achieving this collection of reading, editing, writing and testing goals may move us closer to safe, robust, inexpensive, egalitarian and effective genome editing that can change our environment and ourselves, provided that such strategies are constantly under technical and ethical scrutiny and feedback.

Raj Chari is at the Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts, 02115, USA.

George M. Church is at the Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts, 02115, USA, and at the Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts, 02115, USA.

Correspondence to G.M.C.
gchurch@genetics.med.harvard.edu

doi:10.1038/nrg.2017.59

Published online 30 Aug 2017

- Kosuri, S. & Church, G. M. Large-scale *de novo* DNA synthesis: technologies and applications. *Nat. Methods* **11**, 499–507 (2014).
- Reuter, J. A., Spacek, D. V. & Snyder, M. P. High-throughput sequencing technologies. *Mol. Cell* **58**, 586–597 (2015).
- Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. *Nat. Rev. Genet.* **17**, 333–351 (2016).
- Smithies, O., Gregg, R. G., Boggs, S. S., Koralewski, M. A. & Kucherlapati, R. S. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. *Nature* **317**, 230–234 (1985).
- DeWitt, M. A. *et al.* Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. *Sci. Transl. Med.* **8**, 360ra134 (2016).
- Byrne, S. M., Ortiz, L., Mali, P., Aach, J. & Church, G. M. Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. *Nucleic Acids Res.* **43**, e21 (2015).
- Dever, D. P. *et al.* CRISPR/Cas9 β -globin gene targeting in human haematopoietic stem cells. *Nature* **539**, 384–389 (2016).
- Wang, H. H. *et al.* Programming cells by multiplex genome engineering and accelerated evolution. *Nature* **460**, 894–898 (2009).
- Boeke, J. D. *et al.* The Genome Project-Write. *Science* **353**, 126–127 (2016).
- Robertson, D. E. *et al.* A new dawn for industrial photosynthesis. *Photosynth. Res.* **107**, 269–277 (2011).
- Salhi, A. *et al.* DESM: portal for microbial knowledge exploration systems. *Nucleic Acids Res.* **44**, D624–D633 (2016).
- Fischer, C. R., Klein-Marcuschamer, D. & Stephanopoulos, G. Selection and optimization of microbial hosts for biofuels production. *Metab. Eng.* **10**, 295–304 (2008).
- Isaacs, F. J. *et al.* Precise manipulation of chromosomes *in vivo* enables genome-wide codon replacement. *Science* **333**, 348–353 (2011).
- Lajoie, M. J. *et al.* Genomically recoded organisms expand biological functions. *Science* **342**, 357–360 (2013).
- Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* **42**, D1001–D1006 (2014).

16. Wang, G. *et al.* Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. *Nat. Med.* **20**, 616–623 (2014).
17. Freedman, B. S. *et al.* Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. *Nat. Commun.* **6**, 8715 (2015).
18. Drost, J. *et al.* Sequential cancer mutations in cultured human intestinal stem cells. *Nature* **521**, 43–47 (2015).
19. Matano, M. *et al.* Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat. Med.* **21**, 256–262 (2015).
20. Schwank, G. *et al.* Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* **13**, 653–658 (2013).
21. Liu, J. *et al.* CRISPR/Cas9 facilitates investigation of neural circuit disease using human iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation. *Transl Psychiatry* **6**, e703 (2016).
22. Soldner, F. *et al.* Parkinson-associated risk variant in distal enhancer of α -synuclein modulates target gene expression. *Nature* **533**, 95–99 (2016).
23. Chan, L. Y., Kosuri, S. & Endy, D. Refactoring bacteriophage T7. *Mol. Syst. Biol.* **1**, 2005.0018 (2005).
24. Mandell, D. J. *et al.* Biocontainment of genetically modified organisms by synthetic protein design. *Nature* **518**, 55–60 (2015).
25. Rovner, A. J. *et al.* Recoded organisms engineered to depend on synthetic amino acids. *Nature* **518**, 89–93 (2015).
26. Jinek, M. *et al.* RNA-programmed genome editing in human cells. *eLife* **2**, e00471 (2013).
27. Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013).
28. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
29. Zhang, Y., Buchholz, F., Muysers, J. P. & Stewart, A. F. A new logic for DNA engineering using recombination in *Escherichia coli*. *Nat. Genet.* **20**, 123–128 (1998).
30. Yu, D. *et al.* An efficient recombination system for chromosome engineering in *Escherichia coli*. *Proc. Natl Acad. Sci. USA* **97**, 5978–5983 (2000).
31. Lacroix, B. & Citovsky, V. Transfer of DNA from bacteria to eukaryotes. *mBio* **7**, e00863-16 (2016).
32. Xu, K., Stewart, A. F. & Porter, A. C. G. Stimulation of oligonucleotide-directed gene correction by Red β expression and MSH2 depletion in human HT1080 cells. *Mol. Cells* **38**, 33–39 (2015).
33. Rios, X. *et al.* Stable gene targeting in human cells using single-strand oligonucleotides with modified bases. *PLoS ONE* **7**, e36697 (2012).
34. Igoucheva, O., Alexeev, V. & Yoon, K. Targeted gene correction by small single-stranded oligonucleotides in mammalian cells. *Gene Ther.* **8**, 391–399 (2001).
35. Aarts, M. & te Riele, H. Subtle gene modification in mouse ES cells: evidence for incorporation of unmodified oligonucleotides without induction of DNA damage. *Nucleic Acids Res.* **38**, 6956–6967 (2010).
36. Quadros, R. M. *et al.* Easi-CRISPR: a robust method for one-step generation of mice carrying conditional and insertion alleles using long ssDNA donors and CRISPR ribonucleoproteins. *Genome Biol.* **18**, 92 (2017).
37. Swarts, D. C. *et al.* DNA-guided DNA interference by a prokaryotic Argonaute. *Nature* **507**, 258–261 (2014).
38. Gao, F., Shen, X. Z., Jiang, F., Wu, Y. & Han, C. DNA-guided genome editing using the *Natronobacterium gregoryi* Argonaute. *Nat. Biotechnol.* **34**, 768–773 (2016).
39. Lee, S. H. *et al.* Failure to detect DNA-guided genome editing using *Natronobacterium gregoryi* Argonaute. *Nat. Biotechnol.* **35**, 17–18 (2016).
40. Burgess, S. *et al.* Questions about NgAgo. *Protein Cell* **7**, 913–915 (2016).
41. Javidi-Parsijani, P. *et al.* No evidence of genome editing activity from *Natronobacterium gregoryi* Argonaute (NgAgo) in human cells. *PLoS ONE* **12**, e0177444 (2017).
42. Kim, H. & Kim, J.-S. A guide to genome engineering with programmable nucleases. *Nat. Rev. Genet.* **15**, 321–334 (2014).
43. Chandrasegaran, S. & Carroll, D. Origins of programmable nucleases for genome engineering. *J. Mol. Biol.* **428**, 963–989 (2016).
44. Chevalier, B. S. & Stoddard, B. L. Homing endonucleases: structural and functional insight into the catalysts of intron/intein mobility. *Nucleic Acids Res.* **29**, 3757–3774 (2001).
45. Smith, J. *et al.* A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. *Nucleic Acids Res.* **34**, e149 (2006).
46. Chevalier, B. S. *et al.* Design, activity, and structure of a highly specific artificial endonuclease. *Mol. Cell* **10**, 895–905 (2002).
47. Boissel, S. *et al.* megaTALS: a rare-cleaving nuclease architecture for therapeutic genome engineering. *Nucleic Acids Res.* **42**, 2591–2601 (2014).
48. Wolfs, J. M. *et al.* MegaTevs: single-chain dual nucleases for efficient gene disruption. *Nucleic Acids Res.* **42**, 8816–8829 (2014).
49. Birling, M.-C., Gofflot, F. & Warot, X. Site-specific recombinases for manipulation of the mouse genome. *Methods Mol. Biol.* **561**, 245–263 (2009).
50. Sauer, B. & Henderson, N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. *Proc. Natl Acad. Sci. USA* **85**, 5166–5170 (1988).
51. Turan, S. & Bode, J. Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications. *FASEB J.* **25**, 4088–4107 (2011).
52. Buchholz, F. & Stewart, A. F. Alteration of Cre recombinase site specificity by substrate-linked protein evolution. *Nat. Biotechnol.* **19**, 1047–1052 (2001).
53. Eroshenko, N. & Church, G. M. Mutants of Cre recombinase with improved accuracy. *Nat. Commun.* **4**, 2509 (2013).
54. Santoro, S. W. & Schultz, P. G. Directed evolution of the site specificity of Cre recombinase. *Proc. Natl Acad. Sci. USA* **99**, 4185–4190 (2002).
55. Saraf-Levy, T. *et al.* Site-specific recombination of asymmetric lox sites mediated by a heterotetrameric Cre recombinase complex. *Bioorg. Med. Chem.* **14**, 3081–3089 (2006).
56. Gaj, T. *et al.* Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign. *J. Am. Chem. Soc.* **136**, 5047–5056 (2014).
57. Wallen, M. C., Gaj, T. & Barbas, C. F. Redesigning recombinase specificity for safe harbor sites in the human genome. *PLoS ONE* **10**, e0139123 (2015).
58. Mastroianni, M. *et al.* Group II intron-based gene targeting reactions in eukaryotes. *PLoS ONE* **3**, e3121 (2008).
59. Guo, H. *et al.* Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. *Science* **289**, 452–457 (2000).
60. Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. *Nat. Rev. Genet.* **16**, 299–311 (2015).
61. Tsai, S. Q. & Joung, J. K. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. *Nat. Rev. Genet.* **17**, 300–312 (2016).
62. Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. *Cell* **168**, 20–36 (2017).
63. Mali, P. *et al.* CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat. Biotechnol.* **31**, 833–838 (2013).
64. Ran, F. A. *et al.* Double nicking by RNA-guided CRISPR-Cas9 for enhanced genome editing specificity. *Cell* **154**, 1380–1389 (2013).
65. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420–424 (2016).
66. Nishida, K. *et al.* Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. *Science* **353**, aaf8729 (2016).
67. Yang, L. *et al.* Engineering and optimising deaminase fusions for genome editing. *Nat. Commun.* **7**, 13330 (2016).
68. Fulco, C. P. *et al.* Systematic mapping of functional enhancer-promoter connections with CRISPR interference. *Science* **354**, 769–773 (2016).
69. Canver, M. C. *et al.* BCL11A enhancer dissection by Cas9-mediated *in situ* saturating mutagenesis. *Nature* **527**, 192–197 (2015).
70. Yang, L. *et al.* Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science* **350**, 1101–1104 (2015).
71. Haimovich, A. D., Muir, P. & Isaacs, F. J. Genomes by design. *Nat. Rev. Genet.* **16**, 501–516 (2015).
72. Smith, H. O., Hutchison, C. A., Pflannkuch, C. & Venter, J. C. Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. *Proc. Natl Acad. Sci. USA* **100**, 15440–15445 (2003).
73. Gibson, D. G. *et al.* Complete chemical synthesis, assembly, and cloning of a *Mycoplasma genitalium* genome. *Science* **319**, 1215–1220 (2008).
74. Gibson, D. G. *et al.* Creation of a bacterial cell controlled by a chemically synthesized genome. *Science* **329**, 52–56 (2010).
75. Hutchison, C. A. *et al.* Design and synthesis of a minimal bacterial genome. *Science* **351**, aad6253 (2016).
76. Lartigue, C. *et al.* Creating bacterial strains from genomes that have been cloned and engineered in yeast. *Science* **325**, 1693–1696 (2009).
77. Ostrov, N. *et al.* Design, synthesis, and testing toward a 57-codon genome. *Science* **353**, 819–822 (2016).
78. Dymond, J. S. *et al.* Synthetic chromosome arms function in yeast and generate phenotypic diversity by design. *Nature* **477**, 471–476 (2011).
79. Annaluru, N. *et al.* Total synthesis of a functional designer eukaryotic chromosome. *Science* **344**, 55–58 (2014).
80. Richardson, S. M. *et al.* Design of a synthetic yeast genome. *Science* **355**, 1040–1044 (2017).
81. Shen, Y. *et al.* Deep functional analysis of synII, a 770-kilobase synthetic yeast chromosome. *Science* **355**, eaaf4791 (2017).
82. Xie, Z.-X. *et al.* 'Perfect' designer chromosome V and behavior of a ring derivative. *Science* **355**, eaaf4704 (2017).
83. Zhang, W. *et al.* Engineering the ribosomal DNA in a megabase synthetic chromosome. *Science* **355**, eaaf3981 (2017).
84. Mitchell, L. A. *et al.* Synthesis, debugging, and effects of synthetic chromosome consolidation: synVI and beyond. *Science* **355**, eaaf4831 (2017).
85. Shendure, J. *et al.* Accurate multiplex polony sequencing of an evolved bacterial genome. *Science* **309**, 1728–1732 (2005).
86. Tian, J. *et al.* Accurate multiplex gene synthesis from programmable DNA microchips. *Nature* **432**, 1050–1054 (2004).
87. Gordon, D. *et al.* Long-read sequence assembly of the gorilla genome. *Science* **352**, aae0344 (2016).
88. Loose, M., Malla, S. & Stout, M. Real-time selective sequencing using nanopore technology. *Nat. Methods* **13**, 751–754 (2016).
89. Szalay, T. & Golovchenko, J. A. *De novo* sequencing and variant calling with nanopores using PoreSeq. *Nat. Biotechnol.* **33**, 1087–1091 (2015).
90. Goodwin, S. *et al.* Oxford Nanopore sequencing, hybrid error correction, and *de novo* assembly of a eukaryotic genome. *Genome Res.* **25**, 1750–1756 (2015).
91. Fuller, C. W. *et al.* Real-time single-molecule electronic DNA sequencing by synthesis using polymer-tagged nucleotides on a nanopore array. *Proc. Natl Acad. Sci. USA* **113**, 5235–5238 (2016).
92. Beliveau, B. J. *et al.* Single-molecule super-resolution imaging of chromosomes and *in situ* haplotype visualization using Oligopaint FISH probes. *Nat. Commun.* **6**, 7147 (2015).
93. Zetsche, B. *et al.* Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* **163**, 759–771 (2015).
94. Tsai, S. Q. *et al.* GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* **33**, 187–197 (2015).
95. Frock, R. L. *et al.* Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. *Nat. Biotechnol.* **33**, 179–186 (2015).
96. Kim, D. *et al.* Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. *Nat. Methods* **12**, 237–243 (2015).
97. Lensing, S. V. *et al.* DSBcapture: *in situ* capture and sequencing of DNA breaks. *Nat. Methods* **13**, 855–857 (2016).
98. Osogawa, K. *et al.* A bacterial artificial chromosome library for sequencing the complete human genome. *Genome Res.* **11**, 483–496 (2001).
99. Straub, C., Granger, A. J., Saulnier, J. L. & Sabatini, B. L. CRISPR/Cas9-mediated gene knock-down in post-mitotic neurons. *PLoS ONE* **9**, e105584 (2014).
100. Agah, R. *et al.* Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle *in vivo*. *J. Clin. Invest.* **100**, 169–179 (1997).
101. Suzuki, K. *et al.* *In vivo* genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. *Nature* **540**, 144–149 (2016).
102. Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. *Nucleic Acids Res.* **43**, 9379–9392 (2015).

103. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* **33**, 543–548 (2015).
104. Maruyama, T. *et al.* Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* **33**, 538–542 (2015).
105. Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W. & Elledge, S. J. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. *Nat. Cell Biol.* **14**, 318–328 (2012).
106. Agudelo, D. *et al.* Marker-free coselection for CRISPR-driven genome editing in human cells. *Nat. Methods* **14**, 615–620 (2017).
107. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *eLife* **3**, e04766 (2014).
108. He, X. *et al.* Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. *Nucleic Acids Res.* **44**, e85 (2016).
109. Maresca, M., Lin, V. G., Guo, N. & Yang, Y. Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. *Genome Res.* **23**, 539–546 (2013).
110. Yang, Y. & Seed, B. Site-specific gene targeting in mouse embryonic stem cells with intact bacterial artificial chromosomes. *Nat. Biotechnol.* **21**, 447–451 (2003).
111. Bradley, A. *et al.* The mammalian gene function resource: the International Knockout Mouse Consortium. *Mamm. Genome* **23**, 580–586 (2012).
112. Ordóvaz, L. *et al.* Efficient recombination-mediated cassette exchange in hPSCs to study the hepatocyte lineage reveals AAVS1 locus-mediated transgene inhibition. *Stem Cell Rep.* **5**, 918–931 (2015).
113. Voznyanova, E. *et al.* Efficient Flp-Int HK022 dual RMCE in mammalian cells. *Nucleic Acids Res.* **41**, e125 (2013).
114. Osterwalder, M. *et al.* Dual RMCE for efficient re-engineering of mouse mutant alleles. *Nat. Methods* **7**, 893–895 (2010).
115. Zhang, X., Koolhaas, W. H. & Schnorrer, F. A versatile two-step CRISPR- and RMCE-based strategy for efficient genome engineering in *Drosophila*. *G3 (Bethesda)* **4**, 2409–2418 (2014).
116. Bosley, K. S. *et al.* CRISPR germline engineering — the community speaks. *Nat. Biotechnol.* **33**, 478–486 (2015).
117. Baltimore, D. *et al.* Biotechnology. A prudent path forward for genomic engineering and germline gene modification. *Science* **348**, 36–38 (2015).
118. Church, G. Perspective: encourage the innovators. *Nature* **528**, S7 (2015).
119. Doudna, J. Perspective: embryo editing needs scrutiny. *Nature* **528**, S6 (2015).
120. Schandera, J. & Mackey, T. K. Mitochondrial replacement techniques: divergence in global policy. *Trends Genet.* **32**, 385–390 (2016).
121. Li, L. & Blankenstein, T. Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion. *Nat. Protoc.* **8**, 1567–1582 (2013).
122. Tomizuka, K. *et al.* Double trans-chromosomal mice: maintenance of two individual human chromosomal fragments containing Ig heavy and kappa loci and expression of fully human antibodies. *Proc. Natl Acad. Sci. USA* **97**, 722–727 (2000).
123. DiCarlo, J. E. *et al.* Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res.* **41**, 4336–4343 (2013).
124. Eau Claire, S. F., Zhang, J., Rivera, C. G. & Huang, L. L. Combinatorial metabolic pathway assembly in the yeast genome with RNA-guided Cas9. *J. Ind. Microbiol. Biotechnol.* **43**, 1001–1015 (2016).
125. Wang, S.-Z., Liu, B.-H., Tao, H. W., Xia, K. & Zhang, L. I. A genetic strategy for stochastic gene activation with regulated sparseness (STARS). *PLoS ONE* **4**, e4200 (2009).
126. Gouble, A. *et al.* Efficient in toto targeted recombination in mouse liver by meganuclease-induced double-strand break. *J. Gene Med.* **8**, 616–622 (2006).
127. Gellhaus, K., Cornu, T. I., Heilbronn, R. & Cathomen, T. Fate of recombinant adeno-associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells. *Hum. Gene Ther.* **21**, 543–553 (2010).
128. Robert, M.-A. *et al.* Efficacy and site-specificity of adenoviral vector integration mediated by the phage ϕ C31 integrase. *Hum. Gene Ther. Methods* **23**, 393–407 (2012).
129. Ou, H. *et al.* A highly efficient site-specific integration strategy using combination of homologous recombination and the ϕ C31 integrase. *J. Biotechnol.* **167**, 427–432 (2013).
130. Coluccio, A. *et al.* Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. *Mol. Ther.* **21**, 1695–1704 (2013).
131. Beaton, B. P. *et al.* Inclusion of homologous DNA in nuclease-mediated gene targeting facilitates a higher incidence of bi-allelically modified cells. *Xenotransplantation* **22**, 379–390 (2015).
132. Nakade, S. *et al.* Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. *Nat. Commun.* **5**, 5560 (2014).
133. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* **34**, 339–344 (2016).
134. Wang, H. *et al.* One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).
135. Puchta, H., Dujon, B. & Hohn, B. Homologous recombination in plant cells is enhanced by *in vivo* induction of double strand breaks into DNA by a site-specific endonuclease. *Nucleic Acids Res.* **21**, 5034–5040 (1993).
136. Groth, A. C., Olivares, E. C., Thyagarajan, B. & Calos, M. P. A phage integrase directs efficient site-specific integration in human cells. *Proc. Natl Acad. Sci. USA* **97**, 5995–6000 (2000).
137. Bibikova, M. *et al.* Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. *Mol. Cell Biol.* **21**, 289–297 (2001).
138. Rouet, P., Smih, F. & Jasini, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. *Proc. Natl Acad. Sci. USA* **91**, 6064–6068 (1994).
139. Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome Res.* **13**, 476–484 (2003).
140. Testa, G. *et al.* Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. *Nat. Biotechnol.* **21**, 443–447 (2003).
141. Epinat, J.-C. *et al.* A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells. *Nucleic Acids Res.* **31**, 2952–2962 (2003).
142. Cermak, T. *et al.* Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. *Nucleic Acids Res.* **39**, e82 (2011).
143. Mercer, A. C., Gaj, T., Fuller, R. P. & Barbas, C. F. Chimeric TALE recombinases with programmable DNA sequence specificity. *Nucleic Acids Res.* **40**, 11163–11172 (2012).
144. Gaj, T., Mercer, A. C., Sirk, S. J., Smith, H. L. & Barbas, C. F. A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells. *Nucleic Acids Res.* **41**, 3937–3946 (2013).
145. Owens, J. B. *et al.* Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. *Nucleic Acids Res.* **41**, 9197–9207 (2013).
146. Tsai, S. Q. *et al.* Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. *Nat. Biotechnol.* **32**, 569–576 (2014).
147. Guiling, J. P., Thompson, D. B. & Liu, D. R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. *Nat. Biotechnol.* **32**, 577–582 (2014).
148. Pettersen, E. F. *et al.* UCSF Chimera — a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
149. Zhang, J., McCabe, K. A. & Bell, C. E. Crystal structures of λ exonuclease in complex with DNA suggest an electrostatic ratchet mechanism for processivity. *Proc. Natl Acad. Sci. USA* **108**, 11872–11877 (2011).
150. Chen, Z., Yang, H. & Pavletich, N. P. Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures. *Nature* **453**, 489–494 (2008).
151. Sheng, G. *et al.* Structure-based cleavage mechanism of *Thermus thermophilus* Argonaute DNA guide strand-mediated DNA target cleavage. *Proc. Natl Acad. Sci. USA* **111**, 652–657 (2014).
152. Muñoz, I. G. *et al.* Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. *Nucleic Acids Res.* **39**, 729–743 (2011).
153. Gopaul, D. N., Guo, F. & Van Duyn, G. D. Structure of the Holliday junction intermediate in Cre-loxP site-specific recombination. *EMBO J.* **17**, 4175–4187 (1998).
154. Peisach, E. & Pabo, C. O. Constraints for zinc finger linker design as inferred from X-ray crystal structure of tandem Zif268-DNA complexes. *J. Mol. Biol.* **330**, 1–7 (2003).
155. Mak, A. N.-S., Bradley, P., Cernadas, R. A., Bogdanov, A. J. & Stoddard, B. L. The crystal structure of TAL effector PthXo1 bound to its DNA target. *Science* **335**, 716–719 (2012).
156. Toor, N., Keating, K. S., Taylor, S. D. & Pyle, A. M. Crystal structure of a self-spliced group II intron. *Science* **320**, 77–82 (2008).
157. Nishimasu, H. *et al.* Crystal structure of Cas9 in complex with guide RNA and target DNA. *Cell* **156**, 935–949 (2014).
158. Hatada, S., Nikkuni, K., Bentley, S. A., Kirby, S. & Smithies, O. Gene correction in hematopoietic progenitor cells by homologous recombination. *Proc. Natl Acad. Sci. USA* **97**, 13807–13811 (2000).
159. Wang, H. H. *et al.* Genome-scale promoter engineering by coselection MAGE. *Nat. Methods* **9**, 591–593 (2012).
160. Liu, P.-Q. *et al.* Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases. *Biotechnol. Bioeng.* **106**, 97–105 (2010).
161. Wang, J. *et al.* Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. *Nat. Biotechnol.* **33**, 1256–1263 (2015).
162. Hoban, M. D. *et al.* Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. *Blood* **125**, 2597–2604 (2015).
163. Karakikes, I. *et al.* A comprehensive TALEN-based knockout library for generating human-induced pluripotent stem cell-based models for cardiovascular diseases. *Circ. Res.* **120**, 1561–1571 (2017).
164. Donoho, G., Jasini, M. & Berg, P. Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. *Mol. Cell Biol.* **18**, 4070–4078 (1998).
165. Lin, J. *et al.* Creating a monomeric endonuclease TALE-Scel with high specificity and low genotoxicity in human cells. *Nucleic Acids Res.* **43**, 1112–1122 (2015).
166. Cai, D., Cohen, K. B., Luo, T., Lichtman, J. W. & Sanes, J. R. Improved tools for the Brainbow toolbox. *Nat. Methods* **10**, 540–547 (2013).
167. Ding, Q. *et al.* Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. *Cell Stem Cell* **12**, 393–394 (2013).

Acknowledgements

This work was supported by NIH grant RM1HG008525 “Center for Genomically Engineered Organs”.

Competing interests statement

The authors declare **competing interests**: see Web version for details.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

FURTHER INFORMATION

Church lab CRISPR resources: <http://crispr.med.harvard.edu>

Addgene CRISPR-Cas9 Plasmids and Resources: <http://www.addgene.org/crispr/>

Genome Project—write: <http://engineeringbiologycenter.org/>

ALL LINKS ARE ACTIVE IN THE ONLINE PDF